Drugplain

EXPAREL 13.3 mg/mL

bupivacaine · INJECTION, SUSPENSION, LIPOSOMAL · Pacira Pharmaceuticals, Inc.

No Recall HistoryCurrently in Shortage
Plain English

EXPAREL is a injection, suspension, liposomal containing bupivacaine at 13.3 mg/mL, taken infiltration. Manufactured by Pacira Pharmaceuticals, Inc..

Key Facts

Brand Name
EXPAREL
Generic Name
bupivacaine
NDC Code (Product)
65250-266
Manufacturer
Pacira Pharmaceuticals, Inc.
Strength
13.3 mg/mL
Dosage Form
INJECTION, SUSPENSION, LIPOSOMAL
Route
INFILTRATION
Marketing Status
Application #
NDA022496
Drug Class
Amide Local Anesthetic [EPC]
Marketing Start
01/01/2012

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

off label use882 reports
pain767 reports
drug ineffective705 reports
hypotension532 reports
nausea405 reports
hypoaesthesia374 reports
maternal exposure during pregnancy370 reports
exposure during pregnancy334 reports
drug withdrawal syndrome281 reports
vomiting274 reports

Frequently Asked Questions

What is EXPAREL used for?

EXPAREL contains bupivacaine. It is a injection, suspension, liposomal taken infiltration. Consult your doctor for specific uses.

Is EXPAREL a controlled substance?

EXPAREL is not classified as a controlled substance by the DEA.

What is the generic name for EXPAREL?

The generic name for EXPAREL is bupivacaine. There are 12 other brand versions of bupivacaine.

What is the NDC code for EXPAREL 13.3 mg/mL?

The NDC (National Drug Code) for EXPAREL 13.3 mg/mL is 65250-266, listed by Pacira Pharmaceuticals, Inc..